SCHEMBL745752

SCHEMBL745752

OCCSc1nc2ccccc2s1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.80
CYP2D6 P10635 3/20 0.80
CYP2C19 P33261 3/20 0.71
CYP3A4 P08684 2/20 0.71
CYP2C9 P11712 1/20 0.71
STAT6 P42226 1/20 0.71
MAPK1 P28482 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
HIF1A Q16665 1/20 0.69
ALDH1A1 P00352 7/20 0.68
HSD17B10 Q99714 4/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
HPGD P15428 3/20 0.68
POLB P06746 2/20 0.68
TSHR P16473 1/20 0.68
HTR1A P08908 1/20 0.65
HTR2A P28223 1/20 0.65
HTR7 P34969 1/20 0.65
APEX1 P27695 1/20 0.64
RECQL P46063 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395006 1.00 CYP1A2 (0.80) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL28621136 0.90 CYP1A2 (0.75) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL5837665 0.89 CYP1A2 (1.00) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL7401382 0.87 CYP1A2 (0.71) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL15501200 0.85 CYP1A2 (0.67) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL6141647 0.84 CYP1A2 (0.83) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL25123680 0.84 CYP1A2 (0.65) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL8089129 0.83 FBP1 (0.67) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL9532439 0.83 CYP1A2 (0.80) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL10764021 0.83 CYP1A2 (1.00) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008048554-A2 IMPROVED EPOXY COMPOSITIONS TRILLION SCIENCE, INC. (US) 2008-04-24 WO claimed
US-20080090943-A1 Leuco dyes with a N,N-dialkylamino, N,N-diarylamino, N-alkyl-N-arylamino, N-alkylamino, or N-arylamino group on one of the aromatic rings and a latent curing agent or catalyst activate-able by heat, pressure, or radiation TRILLION, INC. 2008-04-17 US claimed
CN-115362203-B Moisture-curable non-yellowing clear compositions and methods of making the same 迈图高新材料公司 2024-07-16 CN disclosed
US-11859043-B2 Moisture-curable silylated polymer resin composition with reduced moisture sensitivity MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2024-01-02 US disclosed
US-20230106223-A1 MOISTURE-CURABLE NON-YELLOWING CLEAR COMPOSITION AND METHOD OF MAKING THEREOFROM MOMENTIVE PERFORMANCE MATERIALS INC. 2023-04-06 US disclosed
EP-4157911-A1 MOISTURE-CURABLE SILYLATED POLYMER RESIN COMPOSITION WITH REDUCED MOISTURE SENSITIVITY Momentive Performance Materials Inc. (US) 2023-04-05 EP disclosed
EP-4081585-A1 MOISTURE-CURABLE NON-YELLOWING CLEAR COMPOSITION AND METHOD OF MAKING THEREOFROM Momentive Performance Materials Inc. (US) 2022-11-02 EP disclosed
CN-115209790-A Specific THC detection device 韦里特克美国有限公司 2022-10-18 CN disclosed
US-20220291245-A1 SPECIFIC THC DETECTION DEVICE VERITEQUE USA, INC. 2022-09-15 US disclosed
EP-4048141-A1 SPECIFIC THC DETECTION DEVICE Veriteque USA, Inc. (US) 2022-08-31 EP disclosed
CN-110447997-B Cool and comfortable fabric 江苏大毛牛新材料有限公司 2022-02-25 CN disclosed
EP-1382600-B1 Curable compositions containing thiazole functionality NAT STARCH CHEM INVEST (US) 2005-05-04 EP disclosed
EP-1512704-A1 High refractive index, UV-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY (US) 2005-03-09 EP disclosed
US-20050049325-A1 Method of making a high refractive index optical management coating and the coating CITIBANK, N.A., AS COLLATERAL AGENT 2005-03-03 US disclosed
EP-1423363-A1 ORAL ANTIDIABETIC AGENTS Warner-Lambert Company LLC (US) 2004-06-02 EP disclosed
US-6706835-B2 ADHESION PROMOTERS; HIGH STRENGTH BONDING TO METALS; SEMICONDUCTORS, INTEGRATED CIRCUITS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION 2004-03-16 US disclosed
US-20040014903-A1 CURABLE COMPOSITIONS CONTAINING THIAZOLE FUNCTIONALITY HENKEL AG & CO. KGAA (DE) 2004-01-22 US disclosed
EP-1382600-A1 Curable compositions containing thiazole functionality National Starch and Chemical Investment Holding Corporation (US) 2004-01-21 EP disclosed
US-20030171377-A1 Antidiabetic agents BIGGE CHRISTOPHER FRANKLIN (US) 2003-09-11 US disclosed
WO-2003018553-A1 ORAL ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171377-A1 Antidiabetic agents SLC5A1, SLC5A2, GLP1R CYP1A2 971/4885CYP2D6 140/4885CYP2C19 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.